Capsulution and Schering extend cooperation in research and development

Berlin based companies sign agreement to develop new contrast agents and imaging methods in the field of magnetic resonance technology.
(PresseBox) (Berlin, ) Capsulution NanoScience AG, the Berlin based nanotechnology company that is specialised in the development of innovative packaging systems for active substances, has signed a development contract with the Schering AG, Berlin (FSE: SCH; NYSE: SHR). Goal of the cooperation is to develop new contrast agents resp. imaging methods in the field of magnetic resonance technology. The projects focuses on the early diagnosis and treatment of the two most relevant cancer types, the breast and prostate tumors.

Substantial advances in sensitive imaging methods and special directed contrast agents are indispensable for an early diagnosis and individual therapy of these types of cancer. Capsulutions specially tuned nanocapsules can be a great help in this field. Dr. Andreas Voigt, CSO of Capsulution mentioned: “The effects of cancer disease can be reduced, if the personal risk of developing cancer can be determined at an early state via our LBL-Technologie®.” In addition to radio pharmaceutics, it is possible to use special nanotechnology concepts based on the colloid and interface research; for example magnetized nanocapsules which are linked to targeted ligands.

The project called “Eisenherz” is supported by the German Federal Ministry of Education and Research (BMBF) within the framework of the leading innovation program “Nano-for-Life”. Other partners, like Philips Medizin Systeme GmbH, Siemens AG, Max-Planck Institute (MPI) of Colloids and Interfaces or the German Cancer Research Center are also involved in the project.


Capsulution Pharma AG
Volmerstr. 7b
D-12489 Berlin
Dipl.-Kfm. Alexander Herrmann
Capsulution NanoScience AG
Chief Financial Officer (CFO)
Dr. Andreas Briel
Social Media